Al final es que no
The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 8-1 (2 uncertain) that the Phase 3 EMERGE study (the one that was successful at the higher dose) evaluating Biogen's aducanumab in patients with mild AD was not enough to demonstrate efficacy.
Cayendo un 2,3% ya en el Nasdaq
Ya no hay nada más que mirar aquí. Venga, dispérsense
• • •
Missing some Tweet in this thread? You can try to
force a refresh
